InterCure (INCR.TA) Stock Price

InterCure Price

TASE·CLOSED
284.90ILS-13.50 (-4.63 %)
Market closed

Over the last 19 years InterCure grew revenue by 14.3% annually, reaching 238.85 M ILS. Earnings per share have declined at 24.6% per year over the last 10 years. For InterCure, the net margin of -28.4% is up versus -57.2% a few years ago. The consensus 12-month price target for InterCure is 7.14 ILS, about 97.5% below where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 25% above its 52-week low.

InterCure stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of InterCure over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how InterCure stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing InterCure's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

InterCure Stock Price History
DateInterCure Price
7/17/2026284.90 ILS
7/16/2026298.40 ILS
7/15/2026298.80 ILS
7/14/2026299.80 ILS
7/13/2026296.00 ILS
7/10/2026309.00 ILS
7/9/2026296.60 ILS
7/8/2026301.10 ILS
7/7/2026305.00 ILS
7/6/2026313.30 ILS
7/3/2026319.60 ILS
7/2/2026327.50 ILS
7/1/2026338.90 ILS
6/30/2026329.20 ILS
6/29/2026316.10 ILS
6/26/2026316.70 ILS
6/25/2026304.00 ILS
6/24/2026317.00 ILS
6/23/2026318.40 ILS
6/22/2026310.00 ILS
6/19/2026269.80 ILS
6/18/2026276.20 ILS
6/17/2026269.00 ILS
6/16/2026273.90 ILS
6/15/2026269.40 ILS
6/12/2026262.80 ILS
6/11/2026260.90 ILS
6/10/2026257.60 ILS
6/9/2026283.40 ILS
6/8/2026294.40 ILS
6/5/2026299.40 ILS
6/4/2026305.40 ILS
6/3/2026297.30 ILS
6/2/2026300.30 ILS
6/1/2026312.00 ILS
5/29/2026359.00 ILS
5/28/2026295.50 ILS
5/27/2026268.00 ILS
5/26/2026273.00 ILS
5/25/2026270.50 ILS
5/22/2026251.60 ILS
5/21/2026251.60 ILS
5/20/2026251.60 ILS
5/19/2026253.60 ILS
5/18/2026248.10 ILS
5/15/2026242.20 ILS
5/14/2026242.50 ILS
5/13/2026242.50 ILS
5/12/2026246.90 ILS
5/11/2026244.20 ILS
5/8/2026252.00 ILS
5/7/2026252.90 ILS
5/6/2026258.00 ILS
5/5/2026257.10 ILS
5/4/2026249.80 ILS
5/1/2026266.20 ILS
4/30/2026249.30 ILS
4/29/2026252.00 ILS
4/28/2026265.50 ILS
4/27/2026273.80 ILS
4/24/2026257.50 ILS
4/23/2026271.90 ILS
4/22/2026229.40 ILS
4/21/2026229.40 ILS
4/20/2026229.40 ILS
4/17/2026230.30 ILS
4/16/2026228.00 ILS
4/15/2026230.70 ILS
4/14/2026230.40 ILS
4/13/2026237.50 ILS
4/10/2026238.10 ILS
4/9/2026236.60 ILS
4/6/2026236.80 ILS
4/3/2026240.90 ILS
3/31/2026237.50 ILS
3/30/2026237.30 ILS
3/27/2026235.20 ILS
3/26/2026236.50 ILS
3/25/2026236.00 ILS
3/24/2026244.90 ILS
3/23/2026242.60 ILS
3/20/2026242.50 ILS
3/19/2026243.20 ILS
3/18/2026244.40 ILS
3/17/2026243.00 ILS
3/16/2026250.80 ILS
3/13/2026250.80 ILS
3/12/2026250.90 ILS
3/11/2026249.90 ILS
3/10/2026250.60 ILS
3/9/2026259.10 ILS
3/6/2026268.40 ILS
3/5/2026263.90 ILS
3/4/2026268.20 ILS
3/2/2026264.00 ILS
2/27/2026264.40 ILS
2/26/2026252.60 ILS
2/25/2026259.90 ILS
2/24/2026269.40 ILS
2/23/2026276.40 ILS
2/20/2026279.20 ILS
2/19/2026272.50 ILS
2/18/2026277.20 ILS
2/17/2026278.60 ILS
2/16/2026279.50 ILS
2/13/2026279.20 ILS
2/12/2026281.50 ILS
2/11/2026286.80 ILS
2/10/2026290.80 ILS
2/9/2026288.50 ILS
2/6/2026281.70 ILS
2/5/2026272.00 ILS
2/4/2026289.40 ILS
2/3/2026299.20 ILS
2/2/2026289.90 ILS
1/30/2026292.40 ILS
1/29/2026287.90 ILS
1/28/2026289.10 ILS
1/27/2026296.80 ILS
1/26/2026298.00 ILS
1/23/2026298.50 ILS
1/22/2026299.10 ILS
1/21/2026299.90 ILS
1/20/2026305.20 ILS
1/19/2026300.90 ILS
1/16/2026309.20 ILS
1/15/2026304.90 ILS
1/14/2026301.50 ILS
1/13/2026307.70 ILS
1/12/2026313.80 ILS
1/9/2026320.20 ILS
1/8/2026309.50 ILS
1/7/2026314.90 ILS
1/6/2026326.30 ILS
1/5/2026337.00 ILS
1/1/2026325.70 ILS
12/31/2025323.60 ILS
12/30/2025355.30 ILS
12/29/2025357.40 ILS
12/25/2025361.50 ILS
12/24/2025365.40 ILS
12/23/2025382.20 ILS
12/22/2025393.90 ILS
12/18/2025470.00 ILS
12/17/2025469.70 ILS
12/16/2025439.90 ILS
12/15/2025447.20 ILS
12/11/2025403.90 ILS
12/10/2025404.20 ILS
12/9/2025405.00 ILS
12/8/2025412.70 ILS
12/4/2025419.80 ILS
12/3/2025422.20 ILS
12/2/2025425.40 ILS
12/1/2025430.90 ILS
11/27/2025440.50 ILS
11/26/2025429.60 ILS
11/25/2025429.00 ILS
11/24/2025434.10 ILS
11/20/2025437.80 ILS
11/19/2025444.40 ILS
11/18/2025437.50 ILS
11/17/2025450.50 ILS
11/13/2025454.20 ILS
11/12/2025448.50 ILS
11/11/2025456.40 ILS
11/10/2025455.10 ILS
11/6/2025450.00 ILS
11/5/2025457.30 ILS
11/4/2025469.80 ILS
11/3/2025469.80 ILS
10/30/2025461.50 ILS
10/29/2025471.30 ILS
10/28/2025475.80 ILS
10/27/2025484.20 ILS
10/23/2025498.00 ILS
10/22/2025490.40 ILS
10/21/2025503.50 ILS
10/20/2025512.10 ILS
10/16/2025536.30 ILS
10/15/2025533.80 ILS
10/9/2025542.00 ILS
10/8/2025544.10 ILS
9/30/2025548.90 ILS
9/29/2025526.70 ILS
9/25/2025494.70 ILS
9/18/2025514.50 ILS
9/17/2025514.80 ILS
9/16/2025528.60 ILS
9/15/2025520.60 ILS
9/11/2025536.50 ILS
9/10/2025542.20 ILS
9/9/2025547.20 ILS
9/8/2025540.90 ILS
9/4/2025542.40 ILS
9/3/2025545.50 ILS
9/2/2025543.10 ILS
9/1/2025543.00 ILS
8/28/2025536.70 ILS
8/27/2025553.30 ILS
8/26/2025553.90 ILS
8/25/2025560.50 ILS
8/21/2025554.50 ILS
8/20/2025566.30 ILS
8/19/2025566.10 ILS
8/18/2025546.50 ILS
8/14/2025551.90 ILS
8/13/2025557.60 ILS
8/12/2025589.40 ILS
8/11/2025564.40 ILS
8/7/2025498.90 ILS
8/6/2025502.50 ILS
8/5/2025504.90 ILS
8/4/2025505.30 ILS
7/31/2025510.40 ILS
7/30/2025501.40 ILS
7/29/2025506.50 ILS
7/28/2025509.10 ILS
7/24/2025514.40 ILS
7/23/2025516.50 ILS
Access this data via the Eulerpool API
Get Free API Key

InterCure Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
8.93 M ILS
-3.08 M ILS
-5.89 M ILS
Jan 1, 2020
65.04 M ILS
-39.99 M ILS
-37.23 M ILS
Jan 1, 2021
219.68 M ILS
39.50 M ILS
4.69 M ILS
Jan 1, 2022
388.68 M ILS
63.41 M ILS
44.82 M ILS
Jan 1, 2023
355.55 M ILS
31.70 M ILS
-61.96 M ILS
Jan 1, 2024
238.85 M ILS
-49.29 M ILS
-67.80 M ILS
Jan 1, 2025 (e)
404.94 M ILS
52.64 M ILS
27.14 M ILS
Jan 1, 2026 (e)
574.00 M ILS
93.50 M ILS
78.13 M ILS

InterCure Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 22, 2026, 8:03 PM
 
REVENUEM ILS
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM ILS
EBITM ILS
EBIT MARGIN%
NET INCOMEM ILS
NET INCOME GROWTH%
SHARESM
201120122013201420152016201720182019202020212022202320242025e2026e
11.008.008.00–––––8.0065.00219.00388.00355.00238.00404.00574.00
-15.38-27.27–––––––712.50236.9277.17-8.51-32.9669.7542.08
72.7375.0075.00–––––12.5046.1543.3840.7230.4214.7114.7114.71
8.006.006.003.0035.0035.0035.0035.001.0030.0095.00158.00108.0035.0059.4184.41
-1.00-2.00-2.00––1.00-4.00-10.00-3.00-39.0039.0063.0031.00-49.0052.0093.00
-9.09-25.00-25.00–––––-37.50-60.0017.8116.248.73-20.5912.8716.20
-6.0044.00-6.00–––-5.00-12.00-5.00-37.004.0044.00-61.00-67.0027.0078.00
-53.85-833.33-113.64––––140.00-58.33640.00-110.811,000.00-238.649.84-140.30188.89
45.872.685.7745.8745.8712.9016.7817.9623.3026.1546.9245.3545.5745.8745.8745.87
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales InterCure generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue InterCure retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare InterCure's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares InterCure has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against InterCure's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

InterCure stock margins

The InterCure margin analysis displays the gross margin, EBIT margin, as well as the profit margin of InterCure. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for InterCure.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
16.47 %
-34.55 %
-66.02 %
Jan 1, 2020
46.72 %
-61.49 %
-57.25 %
Jan 1, 2021
43.70 %
17.98 %
2.14 %
Jan 1, 2022
40.90 %
16.31 %
11.53 %
Jan 1, 2023
30.47 %
8.91 %
-17.43 %
Jan 1, 2024
14.90 %
-20.64 %
-28.38 %
Jan 1, 2025 (e)
14.90 %
13.00 %
6.70 %
Jan 1, 2026 (e)
14.90 %
16.29 %
13.61 %

InterCure Stock Revenue, EBIT, Earnings per Share

The InterCure earnings per share therefore indicates how much revenue InterCure has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.38 ILS
-0.13 ILS
-0.25 ILS
Jan 1, 2020
2.49 ILS
-1.53 ILS
-1.42 ILS
Jan 1, 2021
4.68 ILS
0.84 ILS
0.10 ILS
Jan 1, 2022
8.57 ILS
1.40 ILS
0.99 ILS
Jan 1, 2023
7.80 ILS
0.70 ILS
-1.36 ILS
Jan 1, 2024
5.21 ILS
-1.07 ILS
-1.48 ILS
Jan 1, 2025 (e)
8.83 ILS
1.15 ILS
0.59 ILS
Jan 1, 2026 (e)
12.51 ILS
2.04 ILS
1.70 ILS

InterCure business model & stock analysis

InterCure Ltd. is a global company in the medical technology industry that focuses on the development, production, and distribution of innovative solutions for the diagnosis and treatment of chronic diseases. The company was founded in Israel in 2000 and is headquartered in Lod.

InterCure SWOT Analysis

Strengths

InterCure Ltd has a strong market presence and brand recognition in the healthcare industry.

The company is backed by a highly skilled and experienced management team.

InterCure has a diverse product portfolio, catering to different segments of the healthcare market.

Weaknesses

InterCure faces stiff competition from other established players in the market.

The company's reliance on a few key suppliers puts it at risk of supply chain disruptions.

InterCure's geographic presence is limited to a few regions, hindering its global expansion opportunities.

Opportunities

InterCure can leverage advancements in technology to develop innovative healthcare solutions.

The growing demand for healthcare services presents an opportunity for InterCure to expand its customer base and market share.

Strategic partnerships and collaborations can help InterCure penetrate new markets and reach a wider audience.

Threats

InterCure faces regulatory uncertainties, which could impact its product development and commercialization processes.

Economic downturns and fluctuations in healthcare spending pose a threat to InterCure's financial performance.

Competitive pricing and cost pressures in the healthcare industry can affect InterCure's profitability.

InterCure Segments

InterCure Revenue by Segment

  • 3 Years

  • Max

Cannabis Segment
Cannabis segment [member]
Reportable segments [member]
Details
Date
Cannabis Segment
Cannabis segment [member]
Reportable segments [member]
Jan 1, 2022
388.68 M ILS
0.00 ILS
388.68 M ILS
Jan 1, 2023
0.00 ILS
355.55 M ILS
355.55 M ILS
Jan 1, 2024
0.00 ILS
238.85 M ILS
238.85 M ILS

InterCure Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

InterCure historical P/E ratio, EBIT multiple, and P/S ratio

InterCure annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

InterCure shares outstanding

The number of shares of InterCure was 45.87 M in 2025. This indicates how many shares InterCure is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
23.30 M Stocks
Jan 1, 2020
26.15 M Stocks
Jan 1, 2021
46.92 M Stocks
Jan 1, 2022
45.35 M Stocks
Jan 1, 2023
45.57 M Stocks
Jan 1, 2024
45.87 M Stocks
Jan 1, 2025 (e)
45.87 M Stocks
Jan 1, 2026 (e)
45.87 M Stocks

InterCure stock splits

In InterCure's history, there have been no stock splits.

Current InterCure forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy85.71 % (6)
Hold14.29 % (1)
Sell0.00 % (0)
12M Price Target
7.14
Last Price
291.70
Currency
ILS
12M Return Potential
-97.55 %
LTM Return
0 %

InterCure Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
11/15/20220.26ILS108.00 MILS2022 Q3
5/16/20220.18ILS92.57 MILS2022 Q1
4/6/20220.14ILS77.03 MILS2021 Q4
11/16/20210.15ILS59.25 MILS2021 Q3
8/16/20210.14ILS39.58 MILS2021 Q2

InterCure shareholder structure

% Name
31.03403%
Rabinovitch (Alexander)
Rabinovitch (Alexander)
4.11229%
Ibex Investors LLC
Ibex Investors LLC
0.46327%
Healthcare Of Ontario Pension Plan
Healthcare Of Ontario Pension Plan
0.23738%
AdvisorShares Investments, LLC
AdvisorShares Investments, LLC
0.21207%
Moore Capital Management, LP
Moore Capital Management, LP
0.10661%
Renaissance Technologies LLC
Renaissance Technologies LLC

InterCure Executives and Management Board

EB

Mr. Ehud Barak

(81)

Chairman of the Board · since 2018

AR

Mr. Alexander Rabinovitch

(51)

Chief Executive Officer, Director · since 2018

AC

Mr. Amos Cohen

(42)

Chief Financial Officer

RL

Mr. Rami Levy

Chief of Operation - Canndoc’s

OM

Mr. Ori Mimon

Co-Chief Executive Officer of Cannolam Ltd

Frequently asked questions about InterCure

InterCure Ltd is a leading company in the healthcare sector. The business model of InterCure revolves around the development and commercialization of innovative medical solutions to improve patient outcomes. With a strong focus on research and development, InterCure aims to provide advanced therapeutic solutions in areas such as respiratory, cardiovascular, and sleep disorders. The company's commitment to excellence and cutting-edge technology enables it to meet the evolving healthcare needs of individuals worldwide. With a customer-centric approach and a dedication to improving quality of life, InterCure Ltd stands out as a prominent player in the healthcare industry.

All fundamentals and in-depth analysis of InterCure

Our stock analysis for InterCure stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of InterCure. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

InterCure Stock
InterCure Revenue→
InterCure Stock
InterCure Net Income→
InterCure Stock
InterCure P/E→
InterCure Stock
InterCure P/S→
InterCure Stock
InterCure EBIT→
InterCure Stock
InterCure Dividend→
InterCure Stock
InterCure Directors Dealings→
InterCure Stock
InterCure Stocks→
InterCure Stock
InterCure Market capitalization→
InterCure Stock
InterCure Debt→
InterCure Stock
InterCure Liabilities→
InterCure Stock
InterCure Equity→
InterCure Stock
InterCure AAQS→
InterCure Stock
InterCure Employees→
InterCure Stock
InterCure ROE→
InterCure Stock
InterCure ROA→
InterCure Stock
InterCure ROCE→
InterCure Stock
InterCure News→
InterCure Stock
InterCure Analyst Price Targets→

Health Stocks

Intermedical Care and Lab Hospital PCLInterconnect VenturesInternational Stem CellIntensity TherapeuticsInternet InfinityIntelligent Bio SolutionsInterojo CoIntellia TherapeuticsInterpace BiosciencesIntelicare HoldingsIntervaccIntegrumAll Stocks A–Z →